Inari Medical (NASDAQ:NARI – Get Free Report) is set to announce its earnings results after the market closes on Monday, October 28th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Inari Medical has set its FY 2024 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.
Inari Medical (NASDAQ:NARI – Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). The business had revenue of $145.82 million for the quarter, compared to the consensus estimate of $143.96 million. Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%. On average, analysts expect Inari Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Inari Medical Trading Down 0.6 %
Inari Medical stock opened at $43.70 on Friday. The company has a market capitalization of $2.54 billion, a P/E ratio of -106.59 and a beta of 1.00. The firm’s fifty day simple moving average is $43.65 and its 200-day simple moving average is $45.86. Inari Medical has a 1-year low of $36.73 and a 1-year high of $67.13.
Insiders Place Their Bets
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a report on Wednesday, October 9th. Robert W. Baird dropped their target price on shares of Inari Medical from $65.00 to $63.00 and set an “outperform” rating on the stock in a report on Wednesday, July 31st. Leerink Partners started coverage on shares of Inari Medical in a report on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 target price on the stock. Canaccord Genuity Group lifted their target price on shares of Inari Medical from $55.00 to $71.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Finally, Piper Sandler reiterated a “neutral” rating and issued a $50.00 target price on shares of Inari Medical in a report on Monday, August 26th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $57.44.
Read Our Latest Research Report on Inari Medical
Inari Medical Company Profile
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Further Reading
- Five stocks we like better than Inari Medical
- Conference Calls and Individual Investors
- Texas Roadhouse Stock Steering for New Highs This Year
- What is Short Interest? How to Use It
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Transportation Stocks Investing
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.